TA
ABBV icon

Tiedemann Advisors’s AbbVie ABBV Stock Holding History

Tiedemann Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.82M Buy
25,535
+6,951
+37% +$1.02M 0.16% 55
2023
Q2 		$2.5M Buy
18,584
+3,813
+26% +$559K 0.11% 70
2023
Q1 		$2.35M Buy
14,771
+3,981
+37% +$609K 0.11% 72
2022
Q4 		$1.74M Buy
10,790
+568
+6% +$87.1K 0.08% 83
2022
Q3 		$1.37M Sell
10,222
-424
-4% -$60.8K 0.08% 94
2022
Q2 		$1.63M Sell
10,646
-2,654
-20% -$406K 0.12% 82
2022
Q1 		$2.16M Sell
13,300
-1,409
-10% -$205K 0.11% 85
2021
Q4 		$1.99M Sell
14,709
-301
-2% -$35.6K 0.1% 90
2021
Q3 		$1.62M Sell
15,010
-6,059
-29% -$692K 0.09% 98
2021
Q2 		$2.38M Sell
21,069
-511
-2% -$57.6K 0.1% 98
2021
Q1 		$2.33M Sell
21,580
-396
-2% -$42.4K 0.1% 95
2020
Q4 		$2.35M Sell
21,976
-1,235
-5% -$119K 0.11% 91
2020
Q3 		$2.03M Buy
23,211
+318
+1% +$29.9K 0.1% 124
2020
Q2 		$2.25M Sell
22,893
-1,091
-5% -$96.1K 0.12% 109
2020
Q1 		$1.83M Sell
23,984
-1,405
-6% -$120K 0.12% 104
2019
Q4 		$2.25M Buy
25,389
+9,227
+57% +$766K 0.11% 108
2019
Q3 		$1.23M Buy
16,162
+4,333
+37% +$297K 0.06% 154
2019
Q2 		$861K Sell
11,829
-1,669
-12% -$131K 0.04% 165
2019
Q1 		$1.09M Sell
13,498
-899
-6% -$73.5K 0.05% 210
2018
Q4 		$1.33M Buy
14,397
+1,957
+16% +$172K 0.07% 172
2018
Q3 		$1.18M Buy
12,440
+2,150
+21% +$204K 0.07% 155
2018
Q2 		$955K Buy
10,290
+3,211
+45% +$314K 0.06% 167
2018
Q1 		$669K Buy
7,079
+16
+0.2% +$1.76K 0.05% 175
2017
Q4 		$683K Sell
7,063
-3,154
-31% -$297K 0.05% 138
2017
Q3 		$766K Sell
10,217
-11,664
-53% -$888K 0.07% 171
2017
Q2 		$1.59M Buy
21,881
+1,302
+6% +$87.5K 0.12% 144
2017
Q1 		$1.34M Buy
20,579
+3,002
+17% +$189K 0.11% 150
2016
Q4 		$1.1M Buy
17,577
+8,308
+90% +$507K 0.11% 136
2016
Q3 		$572K Buy
+9,269
New +$600K 0.12% 88

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tiedemann Advisors's ABBV Position: Q3 2023 in Review

Tiedemann Advisors increased its AbbVie (ABBV) stake by 37% in Q3 2023, buying an estimated $1.02M and bringing the position to 25,535 shares worth $3.82M. The position accounts for 0.16% of the portfolio, ranked #55.

Tiedemann Advisors first reported a position in ABBV in Q3 2016 and has held it in 29 quarters since. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

  • Tiedemann Advisors held 25,535 shares of AbbVie worth $3.82M as of Q3 2023.
  • Tiedemann Advisors bought 6,951 AbbVie shares in Q3 2023, an estimated $1.02M.
  • AbbVie made up 0.16% of Tiedemann Advisors's portfolio in Q3 2023, its #55 holding.
  • Tiedemann Advisors first reported a position in AbbVie in Q3 2016 and has held it in 29 quarters since.
  • 3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Tiedemann Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.